The identification of driver mutations, such as somatic mutations in the epidermal growth factor receptor (EGFR) gene, and the subsequent development of EGFR tyrosine kinase inhibitors (TKIs) as targeted therapy have significantly revolutionized the treatment landscape of these tumours.1, 2, 3. This evidence concerns the gene EGFR and neoplasm.